| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 73351 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
111 |
wyh |
2024-12-19 |
| 73352 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
86 |
h |
2024-12-19 |
| 73353 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
116 |
WYQ |
2024-12-19 |
| 73354 |
1626359-62-3，SPDB-DM4， ADC试剂 |
73 |
kx |
2024-12-19 |
| 73355 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
81 |
WYQ |
2024-12-19 |
| 73356 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
101 |
wyh |
2024-12-19 |
| 73357 |
DOTA-(D)Phe(1)-Tyr(3) |
77 |
h |
2024-12-19 |
| 73358 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
118 |
zyl |
2024-12-19 |
| 73359 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
113 |
WYQ |
2024-12-19 |
| 73360 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
75 |
h |
2024-12-19 |
| 73361 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
87 |
WYQ |
2024-12-19 |
| 73362 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
102 |
wyh |
2024-12-19 |
| 73363 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
128 |
WYQ |
2024-12-19 |
| 73364 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
157 |
kx |
2024-12-19 |
| 73365 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
80 |
h |
2024-12-19 |
| 73366 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
87 |
wyh |
2024-12-19 |
| 73367 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
109 |
zyl |
2024-12-19 |
| 73368 |
CAS: 2285373-84-2 Ethyl (S)-1-((1-((4-((((4-nitrophenoxy)carbonyl) oxy)methyl)phenyl)amino)-1-oxo-5-ureidopenta n-2-yl)carbamoyl)cyclobutane-1-carboxylate |
133 |
WYQ |
2024-12-19 |
| 73369 |
Azido-Phenyl-Amido-SS-Sulfo-NHS Ester， ADC试剂 |
88 |
kx |
2024-12-19 |
| 73370 |
DOTA-βala-K-NOTA-BBN(7-14)NH2 |
99 |
h |
2024-12-19 |
| 73371 |
DBCO-PEG3-acetic-Val-Cit-PAB，主要用于合成抗体偶联药物（ADC） |
87 |
WYQ |
2024-12-19 |
| 73372 |
Mal-PEG4-Val-Ala-PAB-PNP，ADC定制 |
65 |
wyh |
2024-12-19 |
| 73373 |
cas:330970-70-2 Alloc-Val-Ala-OH |
82 |
zyl |
2024-12-19 |
| 73374 |
DOTA-somatostatin receptor analogs DOTA生长抑素受体类似物 |
67 |
h |
2024-12-19 |
| 73375 |
CAS: 2754384-60-4，DBCO-(PEG)3-VC-PAB-MMAE |
68 |
WYQ |
2024-12-19 |
| 73376 |
Fmoc-Gln(Trt)-PAB-OH， ADC试剂 |
110 |
kx |
2024-12-19 |
| 73377 |
CAS: 2994332-18-0 ，DBCO-C4-Val-Cit-PABC-PNP，二苯并环辛炔-C4-缬氨酸-瓜氨酸-PABC-对硝基苯基磷酸酯 |
78 |
WYQ |
2024-12-19 |
| 73378 |
cas:159857-60-0，Fmoc-Lys(MMt)-OH，N-[(9H-芴-9-基甲氧基)羰基]-N'-[(4-甲氧基苯基)二苯基甲基]-L-赖氨酸 |
164 |
kx |
2024-12-19 |
| 73379 |
DBCO-PEG3-Val-Cit-PAB-PNP，二苯并环辛炔-三聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
110 |
WYQ |
2024-12-19 |
| 73380 |
NOTA-anti-HER2 NOTA标记抗人表皮生长因子受体2型(HER2)纳米体 |
108 |
h |
2024-12-19 |
| 73381 |
cas:186023-44-9 Fmoc-Ala-Pro-OH |
97 |
zyl |
2024-12-19 |
| 73382 |
TCO-PEG4-Val-Cit-PAB-PNP，反式环辛烯-四聚乙二醇-缬氨酸-瓜氨酸-PAB-PNP |
79 |
WYQ |
2024-12-19 |
| 73383 |
Boc-Val-Cit CAS:870487-08-4 |
96 |
zyl |
2024-12-19 |
| 73384 |
DOTA-Bn-FGK-Fab DOTA标记抗体片段 |
104 |
h |
2024-12-19 |
| 73385 |
cas:252554-78-2，Fmoc-Ala-Ser (Psi(Me,Me)pro)-OH，(4S)-3-[(2S)-2-[[(9H-芴-9-甲氧基)羰基]氨基]-1-氧代丙基]-2,2-二甲基-4-恶唑烷羧酸 |
60 |
kx |
2024-12-19 |
| 73386 |
DOTA-Nal3-Octreotide DOTANOC DOTA-Nal3-奥曲肽 |
97 |
h |
2024-12-19 |
| 73387 |
cas:2413428-36-9，MC-Gly-Gly-Phe-Gly，(S)-5-苄基-18-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)-4,7,10,13-四氧代-3,6,9,12-四氮杂十八烷-1-酸 |
79 |
kx |
2024-12-19 |
| 73388 |
MC-Val-Cit-PAB-PNP CAS:159857-81-5 |
120 |
zyl |
2024-12-19 |
| 73389 |
cas:2353409-52-4，Mal-amido-PEG8-Val-Gly-PAB-OH，马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY-PAB-羟基 |
70 |
kx |
2024-12-19 |
| 73390 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
72 |
zyl |
2024-12-19 |
| 73391 |
cas:1895916-22-9，MC-Val-Ala-OH， ADC试剂 |
70 |
kx |
2024-12-19 |
| 73392 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，MC-VAL-CIT-阿霉素 |
63 |
kx |
2024-12-19 |
| 73393 |
DOTA−Gal-NAPamide DOTA−Gal-纳帕胺 |
71 |
h |
2024-12-19 |
| 73394 |
DOTA-peptide-Lym-1 radioimmunotherapy DOTA-肽-Lym-1 |
82 |
h |
2024-12-19 |
| 73395 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-cit-PAB-MMAE)， N-二苯并环辛炔-N-双(二聚乙二醇-酰胺-四聚乙二醇-VAL-CIT-PAB-MMAE) |
94 |
kx |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询